Literature DB >> 15534187

Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias.

Constanza Solis1, Antonio Martinez-Bermejo, Thomas P Naidich, Walter E Kaufmann, Kenneth H Astrin, David F Bishop, Robert J Desnick.   

Abstract

BACKGROUND: Acute intermittent porphyria (AIP), due to half-normal hydroxymethylbilane synthase activity,is characterized by acute life-threatening neurologic attacks whose etiology remains unclear. To date, only 3 patients confirmed to have homozygous dominant AIP (HD-AIP) have been described (hydroxymethylbilane synthase genotypes R167Q/R167Q and R167W/R173Q).
OBJECTIVE: To investigate the genetic, biochemical, clinical, and neuroradiologic features of a severely affected infant with HD-AIP.
DESIGN: Clinical, imaging, and genotype/phenotype studies were performed.
RESULTS: The proband, homoallelic for hydroxymethylbilane synthase mutation R167W, had approximately 1% of normal hydroxymethylbilane synthase activity, elevated porphyrins and porphyrin precursors, severe psychomotor delay, and central and peripheral neurologic manifestations. When expressed in vitro, the R167W mutant enzyme had less than 2% of normal activity but was markedly unstable, consistent with the proband's severe phenotype. Mitochondrial respiratory chain enzymes were normal. Neuroradiologic studies revealed a unique pattern of deep cerebral white matter injury, with relative preservation of the corpus callosum, anterior limb of the internal capsule, cerebral gray matter, and infratentorial structures.
CONCLUSIONS: This severely affected patient with HD-AIP expanded the phenotypic spectrum of HD-AIP. His brain magnetic resonance imaging studies suggested selective cerebral oligodendrocyte postnatal involvement in HD-AIP, whereas most structures developed prenatally were intact. These findings indicate that the neurologic manifestations result from porphyrin precursor toxicity rather than heme deficiency and suggest that porphyrin precursor toxicity is primarily responsible for the acute neurologic attacks in heterozygous AIP and other porphyrias.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15534187     DOI: 10.1001/archneur.61.11.1764

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  25 in total

1.  Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice.

Authors:  Carmen Unzu; Ana Sampedro; Itsaso Mauleón; Manuel Alegre; Stuart G Beattie; Rafael Enríquez de Salamanca; Jolanda Snapper; Jaap Twisk; Harald Petry; Gloria González-Aseguinolaza; Julio Artieda; María Sol Rodríguez-Pena; Jesús Prieto; Antonio Fontanellas
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

2.  Genetic and biochemical characterization of 16 acute intermittent porphyria cases with a high prevalence of the R173W mutation.

Authors:  J To-Figueras; C Badenas; C Carrera; C Muñoz; M Milá; M Lecha; C Herrero
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

3.  Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.

Authors:  Makiko Yasuda; Angelika L Erwin; Lawrence U Liu; Manisha Balwani; Brenden Chen; Senkottuvelan Kadirvel; Lin Gan; M Isabel Fiel; Ronald E Gordon; Chunli Yu; Sonia Clavero; Antonios Arvelakis; Hetanshi Naik; L David Martin; John D Phillips; Karl E Anderson; Vaithamanithi M Sadagoparamanujam; Sander S Florman; Robert J Desnick
Journal:  Mol Med       Date:  2015-06-05       Impact factor: 6.354

Review 4.  Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.

Authors:  Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2019-01-18       Impact factor: 4.797

5.  Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.

Authors:  Makiko Yasuda; Lin Gan; Brenden Chen; Chunli Yu; Jinglan Zhang; Miguel A Gama-Sosa; Daniela D Pollak; Stefanie Berger; John D Phillips; Winfried Edelmann; Robert J Desnick
Journal:  Hum Mol Genet       Date:  2019-06-01       Impact factor: 6.150

Review 6.  Acute Intermittent Porphyria in children: A case report and review of the literature.

Authors:  Manisha Balwani; Preeti Singh; Anju Seth; Ekta Malik Debnath; Hetanshi Naik; Dana Doheny; Brenden Chen; Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2016-10-15       Impact factor: 4.797

Review 7.  Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).

Authors:  Herbert L Bonkovsky; Natalia Dixon; Sean Rudnick
Journal:  Mol Genet Metab       Date:  2019-03-06       Impact factor: 4.797

8.  Feline acute intermittent porphyria: a phenocopy masquerading as an erythropoietic porphyria due to dominant and recessive hydroxymethylbilane synthase mutations.

Authors:  Sonia Clavero; David F Bishop; Mark E Haskins; Urs Giger; Raili Kauppinen; Robert J Desnick
Journal:  Hum Mol Genet       Date:  2009-11-24       Impact factor: 6.150

9.  AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function.

Authors:  Makiko Yasuda; David F Bishop; Mary Fowkes; Seng H Cheng; Lin Gan; Robert J Desnick
Journal:  Mol Ther       Date:  2009-10-27       Impact factor: 11.454

Review 10.  Dominant versus recessive: molecular mechanisms in metabolic disease.

Authors:  Johannes Zschocke
Journal:  J Inherit Metab Dis       Date:  2008-10-21       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.